Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Novo Nordisk locks horns with Pfizer

Digest more
 · 23h · on MSN
Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera
Novo Nordisk on Thursday launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to top the deal Pfizer reached last month and teeing up a potential legal battle for the biotech company.

Continue reading

 · 21h · on MSN
Novo Nordisk launches bidding war with Pfizer for US obesity biotech Metsera
BioSpace · 17h
UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer
46mon MSN

Novo Nordisk CEO says job cuts affecting 9,000 staff almost complete

Novo Nordisk has notified employees impacted by the drugmaker's job cuts in the vast majority of its locations although the ...
25m

Novo Nordisk layoffs: Pharma major notifies employees impacted by 9,000 job cuts amid restructuring drive

Novo Nordisk layoffs: Pharma major, Novo Nordisk, on Friday, 31 October 2025, notified its employees who have been impacted ...
New Jersey 101.5
16h

Novo Nordisk quietly cuts over 800 jobs at New Jersey U.S. headquarters

Novo Nordisk cuts over 800 jobs in Plainsboro, part of a global restructuring under the new CEO, reflecting a troubling trend ...
2don MSN

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics

Pfizer
Metsera
Feedback
  • Privacy
  • Terms